The National Institute for Health and Care Excellence

New life-extending treatment given the green light for people with rare form of bile duct cancer

A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
The National Institute for Health and Care Excellence

New take at home drug recommended for people with chronic lymphocytic leukaemia

NICE has recommended a new take‑at‑home tablet for some people with chronic lymphocytic leukaemia whose disease has returned after treatment. The draft guidance could give patients greater choice and ...
The National Institute for Health and Care Excellence

‘Trojan horse’ treatment recommended for people with multiple myeloma

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
The National Institute for Health and Care Excellence

Have your say on NICE’s adoption of the new EQ-5D-5L value set

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...
National Institute for Health and Care Excellence

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. Next review: This guidance will be ...
National Institute for Health and Care Excellence

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

This guidance has been updated and replaced by NICE technology appraisal guidance 946 ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...
National Institute for Health and Care Excellence

Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

We have moved Health technology evaluation 6 to become HealthTech guidance 665. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...